Agios Pharm

AGIO.US
Healthcare · Biotechnology
35.99
-0.98 (-2.65%)
USD · NASDAQ

Company Information

Company Name
Agios Pharm
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US00847X1046
CIK: 0001439222
CUSIP: 00847X104
Currency: USD
Full Time Employees: 539
Phone: 617 649 8600
Fiscal Year End: December
IPO Date: Jul 24, 2013
Description:

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Address:

88 Sidney Street, Cambridge, MA, United States, 02139

People

Directors & Officers

Name Title Year Born
Mr. Brian M. Goff M.B.A. CEO & Director 1969
Ms. Cecilia Jones Chief Financial Officer 1975
Dr. Krishnan Viswanadhan M.B.A., Pharm.D. Chief Strategy & Operations Officer 1979
Mr. James William Burns Chief Legal Officer 1978
Dr. Sarah Gheuens M.D., Ph.D. Chief Medical Officer and Head of Research & Development 1980
Dr. Lewis clayton Cantley Ph.D. Co-Founder 1949
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. Co-Founder 1946
Dr. Craig B. Thompson M.D. Co-Founder 1953
Dr. Shin-San Su Ph.D. Co-Founder 1956
Mr. T. J. Washburn VP, Controller & Principal Accounting Officer 1982

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 02, 2026 James William Burns N/A Sale 3.28K $34.71 $113.85K
Apr 02, 2026 Sarah Gheuens N/A Sale 2.94K $34.71 $102.05K
Apr 02, 2026 Tsveta Milanova N/A Sale 3.26K $34.71 $113.22K
Apr 02, 2026 Cecilia Jones N/A Sale 3.14K $34.71 $109.02K
Mar 05, 2026 Krishnan Viswanadhan N/A Sale 2.96K $27.80 $82.26K
Mar 03, 2026 Gilbert Ray Cisneros, Jr. N/A Purchase N/A $28.48 N/A
Jan 05, 2026 Tsveta Milanova N/A Sale 2.87K $27.02 $77.60K
Dec 30, 2025 Brian Goff N/A Sale 18.70K $27.09 $506.66K
Dec 30, 2025 Cecilia Jones N/A Sale 2.93K $27.09 $79.43K
Dec 30, 2025 James William Burns N/A Sale 2.93K $27.09 $79.43K
Dec 30, 2025 Sarah Gheuens N/A Sale 2.93K $27.09 $79.43K
Dec 30, 2025 Tsveta Milanova N/A Sale 2.93K $27.09 $79.43K
Dec 11, 2025 Gilbert Ray Cisneros, Jr. N/A Purchase N/A $27.46 N/A
Nov 12, 2025 David Scadden N/A Sale 200.00 $43.84 $8.77K
Oct 30, 2025 Sarah Gheuens N/A Sale 200.00 $43.81 $8.76K
Oct 27, 2025 Sarah Gheuens N/A Sale 3.30K $43.92 $145.02K
Oct 08, 2025 David Scadden N/A Sale 200.00 $41.00 $8.20K
Sep 26, 2025 Cecilia Jones N/A Sale 3.65K $36.77 $134.25K
Sep 05, 2025 Theodore James Jr. Washburn N/A Sale 8.55K $36.87 $315.09K
Aug 08, 2025 Brian Goff N/A Sale 11.09K $36.67 $406.49K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 5.75M Mar 31, 2026 9.68% $0.00 9.92%
Farallon Capital Management, L.L.C. 5.68M Mar 31, 2026 9.56% $1.10 10.17%
Vanguard Group Inc 5.59M Dec 31, 2025 9.41% $0.00 -0.19%
State Street Corp 3.36M Mar 31, 2026 5.66% $0.00 8.26%
Armistice Capital, LLC 2.72M Mar 31, 2026 4.57% $1.63 -10.54%
Erste Asset Management GmbH 2.70M Mar 31, 2026 4.55% $0.74 -3.57%
D. E. Shaw & Co LP 2.68M Mar 31, 2026 4.51% $0.05 45.94%
Vanguard Capital Management, LLC 2.63M Mar 31, 2026 4.43% $0.00 0.00%
Lynx1 Capital Management, LP 2.61M Mar 31, 2026 4.39% $13.96 3,179.88%
Vanguard Portfolio Management, LLC 2.61M Mar 31, 2026 4.39% $0.00 0.00%
BNP Paribas Investment Partners SA 1.58M Mar 31, 2026 2.66% $0.06 16.18%
Delaware Management Holdings Inc 1.49M Mar 31, 2026 2.51% $0.09 -12.16%
T. Rowe Price Investment Management,Inc. 1.49M Mar 31, 2026 2.50% $0.03 83,349.55%
Geode Capital Management, LLC 1.47M Mar 31, 2026 2.47% $0.00 3.85%
Susquehanna International Group, LLP 1.34M Mar 31, 2026 2.26% $0.01 17.73%
MPM Oncology Impact Management LP 1.31M Mar 31, 2026 2.20% $3.41 0.22%
Frazier Life Sciences Management, L.P. 1.26M Mar 31, 2026 2.11% $1.09 -1.85%
GW&K Investment Management, LLC 1.21M Mar 31, 2026 2.04% $0.36 0.63%
Dimensional Fund Advisors, Inc. 1.15M Mar 31, 2026 1.94% $0.01 14.66%
Morgan Stanley - Brokerage Accounts 967.53K Mar 31, 2026 1.63% $0.00 8.22%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 BB Biotech AG Ord 3.71M 6.25% ▲ 3.47% Sep 30, 2025
2 State Street® SPDR® S&P® Biotech ETF 2.00M 3.36% ▼ 2.17% Jun 30, 2026
3 Vanguard Total Stock Mkt Idx Inv 1.89M 3.18% ▲ 0.04% Jun 30, 2026
4 Nomura US Small Cap Core Equity 1.70M 2.85% ▲ 43.41% Jun 30, 2026
5 iShares Russell 2000 ETF 1.55M 2.60% ▲ 0.60% Jun 30, 2026
6 Vanguard Small Cap Index 1.36M 2.29% ▲ 1.01% Jun 30, 2026
7 Nomura Small Cap Core I 1.14M 1.92% ▼ 0.82% May 31, 2026
8 Vanguard Small Cap Growth Index Inv 788.66K 1.33% ▲ 4.15% Jun 30, 2026
9 Vanguard Institutional Extnd Mkt Idx Tr 683.80K 1.15% ▲ 3.09% Jun 30, 2026
10 BNP Paribas US Small Cap ClassicC 656.90K 1.10% ▼ 16.90% May 31, 2026

Financial Highlights

Market Cap: $2.20B
EBITDA: $-470.27M
PEG Ratio: $0.00
Book Value: $18.69
Earnings/Share: $-7.26
Profit Margin: 0.00%
Operating Margin: -530.34%
ROA (TTM): -21.69%
ROE (TTM): -32.81%
Revenue (TTM): $66.05M
Revenue/Share (TTM): $1.13
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 137.70%

Valuation Metrics

Enterprise Value: $2.07B
Trailing P/E: 0.00
Forward P/E: 2.47

Shares Statistics

Shares Outstanding: 59.47M
Shares Float: 50.06M
% Insiders: 112.20%
% Institutions: 10,929.70%
Short % Float: 11.26%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$54.03M
Cost of Goods Sold
adjust
$-11.52M
Gross Profit
subtotal
$42.51M
SG&A
adjust
$-180.28M
R&D
adjust
$-334.36M
Operating Income
subtotal
$-472.13M
Other / Non-Operating Items
adjust
$59.35M
Net Income
subtotal
$-412.78M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about AGIO.US!